News | November 07, 2024
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Executes the first project for developing and manufacturing a novel anticancer mAb
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Subscribe To Our Newsletter & Stay Updated
